Aug 18, 2025, 07:42

Cures Within Reach — Clinical Trials to Validate AI-Driven Drug Repurposing

Investigator-initiated Phase I or Phase IIA proof-of-concept clinical trials that validate AI-identified repurposing opportunities for any unsolved disease (preference for rare diseases), using already-approved drugs/biologics and AI-generated data as part of preclinical support.

Eligibility Criteria:

Trials must test an already-approved therapy identified by an AI model and include AI-generated evidence in the preclinical package.
Any disease area eligible; preferences for rare diseases, off-patent therapies, openly accessible AI models, and models from nonprofits/government.

Funding Details:

Budget up to USD 100,000, including a 10% institutional match; additional funds available for community engagement.

Deadline:

Submissions due: August 25, 2025.
Info sessions (CDT): Thu July 17 (8–9 a.m. or 12–1 p.m.); Fri July 25 (8–9 a.m. or 12–1 p.m.).

Where to Go for Further Information:

Email [email protected] with your chosen info-session time, name, and organization to receive a join link.

artificial intelligence clinical trials Community Engagement Cures Within Reach drug repurposing investigator-initiated OncoDaily phase I Phase IIa Proof of Concept rare diseases translational research

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth